Development of Propionibacterium acnes-associated Sarcoidosis During Etanercept Therapy

Although numerous recent studies have reported the development of sarcoidosis in patients treated with tumor necrosis factor alpha (TNF-α) inhibitors, it is unclear whether the pathogenesis of drug-induced sarcoidosis is identical to that of spontaneous sarcoidosis. We herein present the case of a p...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2019/05/15, Vol.58(10), pp.1473-1477
Main Authors: Isshiki, Takuma, Matsuyama, Hisayo, Sakamoto, Susumu, Honma, Naoko, Mikami, Tetuo, Shibuya, Kazutoshi, Eishi, Yoshinobu, Homma, Sakae
Format: Article
Language:English
Subjects:
Case Report
Etanercept
Immunohistochemistry
Inhibitors
Internal medicine
Lymph nodes
Patients
Propionibacterium acnes
Rheumatoid arthritis
Sarcoidosis
TNF-α
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although numerous recent studies have reported the development of sarcoidosis in patients treated with tumor necrosis factor alpha (TNF-α) inhibitors, it is unclear whether the pathogenesis of drug-induced sarcoidosis is identical to that of spontaneous sarcoidosis. We herein present the case of a patient who developed sarcoidosis 6 months after the introduction of etanercept as treatment for rheumatoid arthritis. Typical clinical symptoms with noncaseating epithelioid granulomas detected in a mediastinal lymph node specimen were consistent with the diagnosis of sarcoidosis. Immunohistochemistry revealed Propionibacterium acnes in the noncaseating granulomas. The present findings suggest that Propionibacterium acnes is a cause of sarcoidosis, even when the disease is induced by TNF-α inhibitors.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.2086-18